

**Amendment to Claims:**

1-118. (canceled).

119. (Previously presented) An isolated native sequence polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 194;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 194, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209977, wherein, the nucleic acid encoding said polypeptide is amplified in colon tumors.

120. (Currently amended) The isolated native sequence polypeptide of Claim 119 39 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 194;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 194, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209977, wherein, the nucleic acid encoding said polypeptide is amplified in colon tumors.

121. (Currently amended) The isolated native sequence polypeptide of Claim 119 39 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 194;
- (b) the amino acid sequence of the polypeptide of SEQ ID NO: 194, lacking its associated signal peptide;
- (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209977, wherein, the nucleic acid encoding said polypeptide is amplified in colon tumors.

122. (Currently amended) The isolated native sequence polypeptide of Claim 119 ~~39~~ having at least 95% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 194;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO: 194, lacking its associated signal peptide;
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209977, wherein, the nucleic acid encoding said polypeptide is amplified in colon tumors.
123. (Currently amended) The isolated native sequence polypeptide of Claim 119 ~~39~~ having at least 99% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 194;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO: 194, lacking its associated signal peptide,
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209977, wherein, the nucleic acid encoding said polypeptide is amplified in colon tumors.
124. (Previously presented) An isolated polypeptide comprising:
- (a) the amino acid sequence of the polypeptide of SEQ ID NO: 194;
  - (b) the amino acid sequence of the polypeptide of SEQ ID NO: 194, lacking its associated signal peptide,
  - (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209977, wherein, the nucleic acid encoding said polypeptide is amplified in colon tumors.
125. (Previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 194.

126. (Previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide of SEQ ID NO: 194, lacking its associated signal peptide.

127-128. Canceled.

129. (Previously presented) The isolated polypeptide of Claim 124 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209977.


130. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 124 fused to a heterologous polypeptide.

131. (Previously presented) The chimeric polypeptide of Claim 130, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No.: 39780-2730P1C11). Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully submitted,

Date: July 27, 2006

  
Ginger R. Dreger  
Reg. No. 33,055

**HELLER EHRMAN, LLP**  
**Customer No. 35489**  
275 Middlefield Road  
Menlo Park, California 94025  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

SV 2222065 v1  
7/21/06 3:12 PM (39780.2730)